Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (Nasdaq: ARVN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases through the degradation of disease-causing proteins. The company's proprietary PROTAC® Discovery Engine platform creates Proteolysis-Targeting Chimeras (PROTACs), which leverage the cell's natural protein disposal system to target and degrade specific proteins involved in various diseases.
Founded on groundbreaking research from Yale University by Dr. Craig Crews, Arvinas is at the forefront of transforming protein degradation into novel therapeutic strategies. Their lead candidates include bavdegalutamide (ARV-110) and ARV-766, aimed at treating metastatic castration-resistant prostate cancer, and vepdegestrant (ARV-471), which targets estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Recent achievements highlight Arvinas' robust pipeline and strategic partnerships. In collaboration with Pfizer, vepdegestrant is undergoing Phase 3 trials, showing promising clinical activity and safety in heavily pre-treated breast cancer patients. The company has also initiated a strategic license agreement with Novartis for the global development and commercialization of ARV-766, affirming its potential as a first-in-class treatment for prostate cancer.
Financially, Arvinas maintains a strong position with sufficient resources to fund operations into 2027, bolstered by strategic collaborations and revenue from ongoing license agreements. The company's focus on expanding its clinical trials and exploring new combination therapies positions it for significant impact in oncology and beyond.
For the latest updates on Arvinas' developments and clinical trials, visit their website at www.arvinas.com.
Arvinas, a clinical-stage biotechnology company, will host a live webcast on December 14, 2020, at 8:00 a.m. ET to present updates on its clinical programs for ARV-471 and ARV-110. The presentation will cover the Phase 1 dose escalation studies for ARV-471 in ER positive/HER2 negative breast cancer and ARV-110 for metastatic castrate-resistant prostate cancer, along with details about the newly initiated Phase 2 dose expansion study for ARV-110.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will present at two virtual investor conferences. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a pre-recorded chat with management. The second conference is the 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 3, 2020, with live participation from key executives. Arvinas is dedicated to developing therapies for debilitating diseases using its proprietary PROTAC® platform, targeting proteins causing various conditions.
Arvinas, a clinical-stage biopharmaceutical firm, announced significant updates in its latest press release. The company has initiated Phase 2 dosing for ARV-110 and continues dose escalation for ARV-110 and ARV-471 trials. A collaboration with Pfizer will lead to a Phase 1b trial combining ARV-471 with Ibrance, expected to start fourth quarter 2020. Financial results for Q3 2020 highlighted a net loss of $30.8 million, an increase from $17.7 million in Q3 2019, amid rising R&D expenses of $30.0 million. Cash reserves were $248.6 million, sufficient to support operations into 2022.
Arvinas, Inc. (Nasdaq: ARVN) announced significant updates to its preclinical pipeline, revealing five new programs targeting oncology, immuno-oncology, and neuroscience. The company aims to enhance its leadership in targeted protein degradation with its PROTAC® Discovery Engine. Key targets include BCL6, KRAS, Myc, HPK1, and mHTT, with plans to file INDs by 2022 and 2023. Clinical trials are ongoing for ARV-110 and ARV-471, with data updates expected in Q4 2020. This expansion underscores Arvinas' commitment to addressing high unmet medical needs in various disease areas.
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), will have its President and CEO, John Houston, Ph.D., present at the 3rd Annual Targeted Protein Degradation Summit on October 14-15, 2020. The session, titled "The Promise of PROTAC® Protein Degraders: What’s Next for Arvinas’ Pipeline & Platform," will showcase advancements in Arvinas' PROTAC® technology and introduce new pipeline programs. The company focuses on developing therapies that degrade disease-causing proteins, with two clinical-stage programs targeting advanced prostate and breast cancers.
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced that its Chief Scientific Officer, Ian Taylor, Ph.D., will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on September 10 at 2:25 p.m. ET. A live audio webcast will be available here and on Arvinas’ website. The company is focused on developing therapies for diseases like metastatic prostate cancer and ER+/HER2- breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) has appointed Wendy Dixon, Ph.D., to its Board of Directors, enhancing its leadership with her 40 years of biopharmaceutical experience. Dr. Dixon, recognized for her successful product launches, will provide strategic insight into marketing and business development as Arvinas advances its targeted protein degradation therapies. The company’s two clinical-stage programs, ARV-110 for prostate cancer and ARV-471 for ER+/HER2- breast cancer, are pivotal to its mission of improving patient lives.
Arvinas, a clinical-stage biotechnology company, has appointed Linda Bain to its Board of Directors. Bain, currently CFO of Codiak BioSciences, brings extensive financial and operational experience from previous roles at Avalanche Biotechnologies and bluebird bio, among others. Arvinas' CEO, John Houston, noted her expertise will be vital as the company advances its PROTAC platform, aimed at degrading disease-causing proteins. Arvinas has two clinical programs targeting prostate and breast cancer, reinforcing its commitment to innovative therapeutic solutions.
On June 5, 2020, Arvinas (Nasdaq: ARVN) announced Dr. Ron Peck, Chief Medical Officer, will speak at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11 at 4:40 p.m. ET. A live audio webcast will be available here and on their website at www.arvinas.com.
Arvinas, Inc. (Nasdaq: ARVN) has announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 3, 2020, at 8:30 AM ET. This change is due to the COVID-19 pandemic and related restrictions. Stockholders as of April 6, 2020, are eligible to participate and vote. Registration is required by May 31, 2020, through the Annual Meeting Website. The company encourages all stockholders to vote in advance. Arvinas is focused on developing therapies that degrade disease-causing proteins, with clinical-stage programs targeting prostate and breast cancer.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
What does Arvinas, Inc. specialize in?
What are Arvinas' lead product candidates?
What recent partnerships has Arvinas entered?
What financial position does Arvinas hold for its future operations?
What is PROTAC®?
How does vepdegestrant (ARV-471) work?
What are the key achievements of Arvinas recently?
What is the significance of Arvinas' collaboration with Pfizer?
What diseases is Arvinas targeting with its therapies?
Where can I find more information about Arvinas?
